2929 Walnut Street
Philadelphia, PA 19104

Website: 1315capital.com

Firm Size

  • Assets Under Management (AUM):$1.1 Billion
  • Employees:14
  • Firm Type:Private Equity
  • Focus Areas: Software & Technology


1315 Capital is a private equity firm based in Philadelphia, PA, specializing in providing growth capital to commercial-stage pharmaceutical, medical technology, and healthcare services companies. The firm focuses on companies that have already established their products and services in the market and are seeking funding to scale their operations and expand their market reach. 1315 Capital aims to support companies with innovative healthcare solutions and strong growth potential. The firm's investment strategy involves providing capital in the range of $10 to $60 million, typically as the sole investor or lead investor in syndicate transactions. With a team of experienced professionals, 1315 Capital aims to actively partner with its portfolio companies to drive operational and strategic growth, ultimately aiming to deliver attractive returns for investors while positively impacting the healthcare industry.

Latest News

Powered by

Jun 17, 2024: Primrose Bio Announces Investment from 1315 Capital to Advance Manufacturing Solutions for Next-Generation Therapeutics
Primrose Bio, Inc. ("Primrose," the "Company"), a company focused on developing and licensing its manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines, announced a significant equity investment from 1315 Capital, a Philadelphia -based, healthcare-focused growth equity firm.

Feb 01, 2024: Triple Ring Technologies and 1315 Capital Announce Strategic Growth Partnership
Triple Ring Technologies ("Triple Ring"), The Co-Development Company for Medical Device and Life Sciences, proudly announces a significant growth capital investment from 1315 Capital, a Philadelphia -based, healthcare-focused growth equity firm. The company was advised by Rob King and Crewe Capital, out of their New York office.

Oct 23, 2023: 1315 Capital Closes Two Funds, Raising over $500 Million to Invest in Commercial-Stage Healthcare Companies
1315 Capital , a private investment firm that provides growth capital to commercial-stage healthcare services, pharmaceutical & medical technology outsourcing, medical technology, and health & wellness companies, today announced the final closes of 1315 Capital III ("Fund III") and 1315 Capital Emerging Growth and Buyout ("EGB"), exceeding the targets of $350 million and $150 million , respectively. Both funds include commitments from endowments, foundations, public and private pensions, business entities, and family offices.